Levacetylleucine

Levacetylleucine

SCHEMBL756572

CC(=O)N[C@H](CC(C)C)C(=O)O.CCOc1cc([C@@H](N)CS(C)(=O)=O)ccc1OC

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
PDE4B Q07343 15/20 0.45
PDE4C Q08493 12/20 0.45
PDE4A P27815 9/20 0.45
PDE4D Q08499 9/20 0.45
HTR2B P41595 1/20 0.45
FOLH1 Q04609 2/20 0.45
ATM Q13315 1/20 0.44
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levacetylleucine SCHEMBL7084218 1.00 LMNA (0.45) LMNAPDE4BPDE4CPDE4APDE4D
Acetylleucine SCHEMBL20474775 1.00 LMNA (0.45) LMNAPDE4BPDE4CPDE4APDE4D
Levacetylleucine SCHEMBL302605 1.00 LMNA (0.45) LMNAPDE4BPDE4CPDE4APDE4D
Levacetylleucine SCHEMBL21229236 1.00 LMNA (0.45) LMNAPDE4BPDE4CPDE4APDE4D
Levacetylleucine SCHEMBL702915 0.94 PDE4B (0.43) LMNAPDE4BPDE4CPDE4APDE4D
Levacetylleucine SCHEMBL703860 0.89 FOLH1 (0.42) LMNAPDE4BPDE4CPDE4APDE4D
Leucine SCHEMBL18074074 0.87 PDE4B (0.48) PDE4BPDE4CPDE4APDE4DHTR2B
Leucine SCHEMBL18074075 0.87 PDE4B (0.48) PDE4BPDE4CPDE4APDE4DHTR2B
SCHEMBL2670612 0.87 LMNA (0.47) LMNAPDE4BPDE4CPDE4APDE4D
SCHEMBL21250512 0.85 FOLH1 (0.45) LMNAPDE4BPDE4CPDE4APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10611775-B2 Thiophene derivatives TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2020-04-07 US disclosed
US-20190322684-A1 THIOPHENE DERIVATIVES TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2019-10-24 US disclosed
US-10385062-B2 Thiophene derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-08-20 US disclosed
US-20170197982-A1 THIOPHENE DERIVATIVES GANZHOU HEMAY PHARMACEUTICAL CO., LTD. (CN) 2017-07-13 US disclosed
US-9630975-B2 Thiophene derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2017-04-25 US disclosed
US-8952178-B2 Thiophene derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-02-10 US disclosed
US-20140255342-A1 THIOPHENE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-09-11 US disclosed
EP-2431371-B1 THIOPHENE DERIVATIVES TIANJIN HEMAY BIO TECH CO LTD (CN) 2013-10-09 EP disclosed
US-20120107269-A1 THIOPHENE DERIVATIVES Tianjin Hemay Biotech Co., Ltd (CN) 2012-05-03 US disclosed
EP-2431371-A1 THIOPHENE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2012-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385062-B2 Thiophene derivatives TSHR, RB1, TAS2R7 LMNA 4878/4885PDE4B 1282/4885PDE4C 1755/4885
US-20120107269-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 LMNA 4878/4885PDE4B 1282/4885PDE4C 1755/4885
US-10611775-B2 Thiophene derivatives TSHR, RB1, TAS2R7 LMNA 4878/4885PDE4B 1282/4885PDE4C 1755/4885
US-20170197982-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 LMNA 4878/4885PDE4B 1282/4885PDE4C 1755/4885
US-20140255342-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 LMNA 4878/4885PDE4B 1282/4885PDE4C 1755/4885
US-20190322684-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 LMNA 4878/4885PDE4B 1282/4885PDE4C 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.